8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
September 16, 2015
HEMISPHERX BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
|
| | | | |
Delaware | | 0‑27072 | | 52-0845822 |
(state or other juris- | | (Commission | | (I.R.S. Employer |
diction of incorporation) | | File Number) | | (Identification No.) |
|
| | |
1617 JFK Boulevard, Suite 500, Philadelphia, PA | | 19103 |
(Address of principal executive offices) | | (Zip Code) |
| | |
Registrant's telephone number, including area code: (215) 988-0080 |
|
1617 JFK Boulevard, Suite 660, Philadelphia, PA 19103 |
(Former name or former address, if changed since last report) |
|
| |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
| |
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07 Submission of Matters to a Vote of Security Holders
The Company’s Annual Meeting of Stockholders for 2015 was held on September 16, 2015. The requisite quorum for the meeting of 40.0% was present. At the meeting, stockholders voted as follows:
Election of Directors:
Nominees For Withheld Broker Non-Votes
William A. Carter, MD 32,613,832 1,930,133 101,032,363
Thomas K. Equels, Esq. 32,738,350 1,805,615 101,032,363
Peter W. Rodino III, Esq. 19,202,426 15,341,539 101,032,363
William M. Mitchell, MD 19,177,625 15,366,340 101,032,363
Iraj-Eq Kiani, PhD. 19,256,569 15,287,396 101,032,363
Ratification of the appointment of McGladrey LLP as our independent accountants:
|
| | |
For: 130,701,921 | Against: 3,145,783 | Abstain: 1,728,624 |
Advisory, non-binding, vote on approval of the compensation of the Company’s Named Executive Officers:
For: 15,516,793 Against: 18,499,981 Abstain: 527,191 Broker Non-Vote: 101,032,363
Approval of Board Authorization to utilize 60,000,000 shares of Common Stock for fund raising purposes:
For: 29,914,283 Against: 4,374,706 Abstain: 254,976 Broker Non-Vote: 101,032,363
Approval of an amendment to the Hemispherx Biopharma, Inc. 2009 Equity Incentive Plan:
For: 29,387,277 Against: 4,896,523 Abstain: 260,165 Broker Non-Vote: 101,032,363
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HEMISPHERX BIOPHARMA, INC.
September 17, 2015 By: /s/ William A. Carter
William A. Carter,
Chief Executive Officer